Retinal Vein Occlusion - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 7 and 1 respectively.Retinal Vein Occlusion.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Retinal Vein Occlusion Overview 7
Therapeutics Development 8
Pipeline Products for Retinal Vein Occlusion - Overview 8
Retinal Vein Occlusion - Therapeutics under Development by Companies 9
Retinal Vein Occlusion - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Retinal Vein Occlusion - Products under Development by Companies 13
Retinal Vein Occlusion - Companies Involved in Therapeutics Development 14
Aerpio Therapeutics, Inc. 14
Clearside BioMedical, Inc. 15
Formycon AG 16
Kala Pharmaceuticals, Inc. 17
Mabion SA 18
NicOx S.A. 19
Ohr Pharmaceutical Inc. 20
Precision Ocular Ltd 21
ThromboGenics NV 22
Retinal Vein Occlusion - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(aflibercept + triamcinolone acetonide) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
aflibercept biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AKB-9778 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
HO-10 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LKA-651 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
loteprednol etabonate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NCX-422 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NCX-434 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ocriplasmin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ranibizumab biosimilar - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ranibizumab biosimilar - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule for Ophthalmology and Orphan Diseases - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
squalamine lactate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Retinal Vein Occlusion - Dormant Projects 66
Retinal Vein Occlusion - Discontinued Products 67
Retinal Vein Occlusion - Product Development Milestones 68
Featured News & Press Releases 68
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 68
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 68
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 69
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 70
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 70
Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 71
Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 72
Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 73
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 74

Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H2 2016 14
Retinal Vein Occlusion - Pipeline by Clearside BioMedical, Inc., H2 2016 15
Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2016 16
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 17
Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2016 18
Retinal Vein Occlusion - Pipeline by NicOx S.A., H2 2016 19
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H2 2016 20
Retinal Vein Occlusion - Pipeline by Precision Ocular Ltd, H2 2016 21
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Assessment by Combination Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Retinal Vein Occlusion - Dormant Projects, H2 2016 66
Retinal Vein Occlusion - Discontinued Products, H2 2016 67